Complement component 7 is associated with total- and cardiac death in chest-pain patients with suspected acute coronary syndrome.
Acute Coronary Syndrome
/ blood
Aged
Aged, 80 and over
Angina Pectoris
/ blood
Argentina
Biomarkers
/ blood
C-Reactive Protein
/ analysis
Cause of Death
Complement C7
/ analysis
Female
Hospitalization
Humans
Inflammation Mediators
/ blood
Male
Middle Aged
Norway
Predictive Value of Tests
Prognosis
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
Acute coronary syndrome
All-cause mortality
Cardiac death
Complement component 7
High-sensitivity C-reactive protein
Prognostic biomarkers
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
14 10 2021
14 10 2021
Historique:
received:
18
07
2021
accepted:
05
10
2021
entrez:
15
10
2021
pubmed:
16
10
2021
medline:
18
1
2022
Statut:
epublish
Résumé
Complement activation has been associated with atherosclerosis, atherosclerotic plaque destabilization and increased risk of cardiovascular events. Complement component 7 (CC7) binds to the C5bC6 complex which is part of the terminal complement complex (TCC/C5b-9). High-sensitivity C-reactive protein (hsCRP) is a sensitive marker of systemic inflammation and may reflect the increased inflammatory state associated with cardiovascular disease. To evaluate the associations between CC7 and total- and cardiac mortality in patients hospitalized with chest-pain of suspected coronary origin, and whether combining CC7 with hsCRP adds prognostic information. Baseline levels of CC7 were related to 60-months survival in a prospective, observational study of 982 patients hospitalized with a suspected acute coronary syndrome (ACS) at 9 hospitals in Salta, Argentina. A cox regression model, adjusting for conventional cardiovascular risk factors, was fitted with all-cause mortality, cardiac death and sudden cardiac death (SCD) as the dependent variables. A similar Norwegian population of 871 patients was applied to test the reproducibility of results in relation to total death. At follow-up, 173 patients (17.7%) in the Argentinean cohort had died, of these 92 (9.4%) were classified as cardiac death and 59 (6.0%) as SCD. In the Norwegian population, a total of 254 patients (30%) died. In multivariable analysis, CC7 was significantly associated with 60-months all-cause mortality [hazard ratio (HR) 1.26 (95% confidence interval (CI), 1.07-1.47) and cardiac death [HR 1.28 (95% CI 1.02-1.60)], but not with SCD. CC7 was only weakly correlated with hsCRP (r = 0.10, p = 0.002), and there was no statistically significant interaction between the two biomarkers in relation to outcome. The significant association of CC7 with total death was reproduced in the Norwegian population. CC7 was significantly associated with all-cause mortality and cardiac death at 60-months follow-up in chest-pain patients with suspected ACS. ClinicalTrials.gov Identifier: NCT01377402, NCT00521976.
Sections du résumé
BACKGROUND
Complement activation has been associated with atherosclerosis, atherosclerotic plaque destabilization and increased risk of cardiovascular events. Complement component 7 (CC7) binds to the C5bC6 complex which is part of the terminal complement complex (TCC/C5b-9). High-sensitivity C-reactive protein (hsCRP) is a sensitive marker of systemic inflammation and may reflect the increased inflammatory state associated with cardiovascular disease.
AIM
To evaluate the associations between CC7 and total- and cardiac mortality in patients hospitalized with chest-pain of suspected coronary origin, and whether combining CC7 with hsCRP adds prognostic information.
METHODS
Baseline levels of CC7 were related to 60-months survival in a prospective, observational study of 982 patients hospitalized with a suspected acute coronary syndrome (ACS) at 9 hospitals in Salta, Argentina. A cox regression model, adjusting for conventional cardiovascular risk factors, was fitted with all-cause mortality, cardiac death and sudden cardiac death (SCD) as the dependent variables. A similar Norwegian population of 871 patients was applied to test the reproducibility of results in relation to total death.
RESULTS
At follow-up, 173 patients (17.7%) in the Argentinean cohort had died, of these 92 (9.4%) were classified as cardiac death and 59 (6.0%) as SCD. In the Norwegian population, a total of 254 patients (30%) died. In multivariable analysis, CC7 was significantly associated with 60-months all-cause mortality [hazard ratio (HR) 1.26 (95% confidence interval (CI), 1.07-1.47) and cardiac death [HR 1.28 (95% CI 1.02-1.60)], but not with SCD. CC7 was only weakly correlated with hsCRP (r = 0.10, p = 0.002), and there was no statistically significant interaction between the two biomarkers in relation to outcome. The significant association of CC7 with total death was reproduced in the Norwegian population.
CONCLUSIONS
CC7 was significantly associated with all-cause mortality and cardiac death at 60-months follow-up in chest-pain patients with suspected ACS.
CLINICAL TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT01377402, NCT00521976.
Identifiants
pubmed: 34649504
doi: 10.1186/s12872-021-02306-w
pii: 10.1186/s12872-021-02306-w
pmc: PMC8515738
doi:
Substances chimiques
Biomarkers
0
Complement C7
0
Inflammation Mediators
0
C-Reactive Protein
9007-41-4
Banques de données
ClinicalTrials.gov
['NCT01377402', 'NCT00521976']
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
496Informations de copyright
© 2021. The Author(s).
Références
BMC Cardiovasc Disord. 2011 Sep 29;11:57
pubmed: 21958326
J Intern Med. 2021 Oct;290(4):894-909
pubmed: 34237166
Immunol Res. 2011 Oct;51(1):45-60
pubmed: 21850539
Immunol Res. 2016 Feb;64(1):1-13
pubmed: 26091721
Atherosclerosis. 1985 Apr;55(1):35-50
pubmed: 2408631
Immunol Lett. 2014 Nov;162(1 Pt A):262-8
pubmed: 25256773
Eur Heart J. 2005 Nov;26(21):2294-9
pubmed: 15917276
Am J Cardiol. 2002 Apr 15;89(8):909-12
pubmed: 11950426
Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1214-9
pubmed: 11451754
Atherosclerosis. 2004 Dec;177(2):383-9
pubmed: 15530914
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
Circulation. 1990 Jan;81(1):156-63
pubmed: 2297823
Atherosclerosis. 2007 Dec;195(2):e195-202
pubmed: 17714718
J Am Coll Cardiol. 2016 Feb 16;67(6):712-723
pubmed: 26868696
Am J Med. 1995 Apr;98(4):357-64
pubmed: 7709948
JAMA. 2016 Jun 21;315(23):2532-41
pubmed: 27327800
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Mol Immunol. 2014 Oct;61(2):126-34
pubmed: 25037633
Eur J Prev Cardiol. 2016 Jul;23(11):1130-40
pubmed: 26635361
Circulation. 1999 Jul 6;100(1):96-102
pubmed: 10393687
Mol Med Rep. 2016 Dec;14(6):5350-5356
pubmed: 27840920
Lancet. 1997 Feb 15;349(9050):462-6
pubmed: 9040576
Lancet. 2010 Jan 9;375(9709):132-40
pubmed: 20031199
Am J Cardiol. 1990 Jan 15;65(3):168-72
pubmed: 2296885
Arteriosclerosis. 1989 Nov-Dec;9(6):802-11
pubmed: 2480105
Atherosclerosis. 2015 Aug;241(2):480-94
pubmed: 26086357
Diabetes Care. 2012 Apr;35(4):911-7
pubmed: 22357179
Am Heart J. 2012 Nov;164(5):786-92
pubmed: 23137511
Atherosclerosis. 2018 Apr;271:245-251
pubmed: 29402404
Am J Cardiol. 2007 Apr 1;99(7):890-5
pubmed: 17398178
Circulation. 2004 Jul 13;110(2):128-34
pubmed: 15197143